STADA opens new facility in Romania for sustainable medicines supply in Europe

Business Forum
STADA has opened a major new production site and supply-chain hub in Turda, Romania, that will contribute to security of medicines supply in Europe by supplying more than 150 million packs per year. Following a total investment of more than €70 million ($75 million), the facility is now fully validated and approved, with initial shipments underway.

The Turda facility supports the sustainable supply of prescription medicines such as antidepressants, antihistamines and anti-inflammatory agents, as well as medicines to treat diabetes, high cholesterol levels and hypertension. Furthermore, it is shipping a wide assortment of consumer healthcare products to enable self-care from its automated warehouse that has capacity for 7,400 pallets. The 100,000 sq m greenfield site, on which construction started in late 2022, offers room for expansion in the future.

By leveraging industry-leading design concepts and technologies, the production and supply-chain hub located in Cluj County reinforces STADA's commitment to sustainable medicines provision in Europe. Ecologically-friendly packaging materials are a key focus, while photovoltaic solar panels and low-energy lighting minimize carbon emissions. Already, around 45% of STADA's electricity consumption comes from renewable sources, helping STADA to rank among the top 6% of pharma companies worldwide on sustainability.

“Amid the ongoing discussions about how best to secure a sustainable supply of critical medicines in Europe, STADA is proud to make this major EU investment that will help to ensure patients can access the medicines they need,” stated STADA's Chief Technical Officer, Miguel Pagan. “Having implemented industry-leading concepts in design, construction and energy conservation, the group is also playing its part on environmental sustainability.”

The site in Turda's Aries Industrial Park is strategically located at the heart of STADA's European markets, and within the European Union, offering close connections and synergies with testing laboratories in Timisoara, Romania, as well as several key production facilities in the Western Balkans region and the group's consumer healthcare center of excellence in Třinec, Czech Republic.

“Working closely with national and local authorities, this state-of-the-art facility has created almost 400 jobs in Cluj County,” explained Mihai Fugarevici, general manager of STADA Romania. ”The Turda site further enhances our capacity to deliver quality healthcare products, not only in Romania, but throughout Europe.”

STADA Arzneimittel AG is headquartered in Bad Vilbel, Germany. The company focuses on a three-pillar strategy consisting of consumer healthcare products, generics and specialty pharma. Worldwide, STADA Arzneimittel AG sells its products in more than 100 countries. In financial year 2023, STADA achieved group revenues of €3,734.8 million and reported earnings before interest, taxes, depreciation and amortization (EBITDA) of €802.1 million. As of 31 December 2023, STADA employed 11,667 people worldwide.

RECOMMENDED
RECOMMENDED FROM THE HOME PAGE
Electro-Alfa plans IPO on BVB
Finance

Electro-Alfa plans IPO on BVB

Electro-Alfa International, a Romanian electrical equipment manufacturer, has announced plans for an Initial Public Offering (IPO) on the Bucharest Stock Exchange (BVB).

Industry

Life sciences M&A surges 81% as big pharma hunts for growth, says EY

Global life sciences M&A activity increased by 81% in 2025 to $240 billion, driven by Big Pharma's large-scale deals, despite fewer overall transactions. The surge reflects companies prioritising innovations ready for launch as they face widening growth gaps.

Finance

Romania launches first 2026 Fidelis bond IPO on stock exchange

Romania's Ministry of Finance will conduct its first public offering of Fidelis government bonds for 2026 between January 16 and 23 on the Bucharest Stock Exchange. This marks the 32nd offering since the Fidelis program resumed in July 2020.

READ MORE
Business Forum  |  16 January, 2026 at 5:00 PM
Business Forum  |  16 January, 2026 at 4:13 PM